At CCRPS, we will be continuing all remote learning courses for our students. We suggest you stay at home to review each module rather than at a library or coffee shop to protect both yourself and your family members. If you need an extension on your course due to the current events, please contact Dr.Desai at pdesai@ccrps.org any time.
COVID-19 Resources for Clinical Researchers
We wanted to share resources which will help curious minds in clinical research (like ourselves) stay current with the current, quick changes occurring in response to COVID-19.
Please keep updated on your institution’s IRB policies for trials involving direct patient contact as they may be paused, delayed, or IRB approval will not be provided unless the trial start date is after the current precautions in place.
COVID-19 & Management - EMCRIT
This resource by Emergency Critical Care provides clinically relevant information on the pathophysiology, clinical diagnoses, testing, and potential treatments for COVID-19.
Mass General COVID-19 Grand Rounds
The Mass General Grand Rounds on 3/12/20 by the BCPR provides information on the Timeline of Spread, Epidemiology, COVID-19 pathophysiology, Vaccine development, Pharmacology, and more important topics needed to understand the current status of the pandemic.
Vaccine Trial for SARS COV-2
The Vaccine Trial is currently in Phase 1 with a current estimated end date of January 2021 at Kaiser in Seattle,WA.
ClinicalTrials.Gov Trials for COVID-19
There are over 80 Clinical Trials being conducted for COVID-19 listed in the Clinicaltrials.gov website useful for all clinical researchers to review.
CDC COVID-19 Page
The CDC is the main source of clinical practice and laboratory practice guidelines relevant to all healthcare professionals.
UptoDate Open Access Page on COVID-19
UptoDate has now made their COVID-19 page (draft; not completed peer-review) available with citations of important literature in the past few months. This is a great reference tool.
We wish you well and hope you stay safe, practice social distancing as needed, and use this opportunity if home to learn more.
Clinical Trials on COVID-19 3/17/2020
All trial information below is sourced from the clinicaltrials.gov website.
The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19
Drug: Huaier Granule
Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function
18 Years to 75 Years (Adult, Older Adult)
Phase 2|Phase 3
N=550
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
April 1, 2020 - September 1, 2020
https://ClinicalTrials.gov/show/NCT04291053
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)
Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events
18 Years to 80 Years (Adult, Older Adult)
Not Applicable
N=0
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 2020 - April 2020
GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
https://ClinicalTrials.gov/show/NCT04287686
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.
Drug: TCM prescriptions
The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score
18 Years to 75 Years (Adult, Older Adult)
N=340
Observational Model: Cohort|Time Perspective: Prospective
March 2, 2020-May 2020
Huai'an fourth people's Hospital, Huaian, Jiangsu, China
https://ClinicalTrials.gov/show/NCT04306497
The COVID-19 Mobile Health Study (CMHS)
Other: nCapp, a cell phone-based auto-diagnosis system
Accuracy of nCapp COVID-19 risk diagnostic model
18 Years to 90 Years (Adult, Older Adult)
N=450
Observational Model: Cohort|Time Perspective: Prospective
February 14, 2020-May 31, 2020
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04275947
A Pilot Study of Sildenafil in COVID-19
Drug: Sildenafil citrate tablets
Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event
18 Years and older (Adult, Older Adult)
Phase 3
N=10
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 9, 2020-November 9, 2020
Department and Institute of Infectious Disease, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04304313
Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study
28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement
18 Years and older (Adult, Older Adult)
N=8
Observational Model: Case-Only|Time Perspective: Retrospective
February 14, 2020-February 25, 2020
Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong
https://ClinicalTrials.gov/show/NCT04285801
Safety and Immunity of Covid-19 aAPC Vaccine
Biological: Pathogen-specific aAPC
Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable
6 Months to 80 Years (Child, Adult, Older Adult)
Phase 1
N=100
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 15, 2020-December 31, 2024
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
https://ClinicalTrials.gov/show/NCT04299724
Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic
Drug: Antiviral treatment and prophylaxis|Other: Standard Public Health measures
Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug
18 Years and older (Adult, Older Adult)
Phase 3
N= 3040
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
March 15, 2020-July 15, 2020
https://ClinicalTrials.gov/show/NCT04304053
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate
Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine
16 Years to 99 Years (Child, Adult, Older Adult)
Phase 2
N=150
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 11, 2020-May 2020
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
https://ClinicalTrials.gov/show/NCT04307693
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
Drug: Remdesivir|Drug: Standard of Care
Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation
18 Years and older (Adult, Older Adult)
Phase 3
N=400
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 6, 2020-May 2020
Providence Regional Medical Center Everett, Everett, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore
https://ClinicalTrials.gov/show/NCT04292899
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Drug: Remdesivir|Drug: Standard of Care
Proportion of Participants Discharged by Day 14|Proportion of Participants With Treatment Emergent Adverse Events Leading to Study Drug Discontinuation
18 Years and older (Adult, Older Adult)
Phase 3
N=600
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 2020
May 2020
Providence Medical Research Center, Everett, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore
https://ClinicalTrials.gov/show/NCT04292730
Tetrandrine Tablets Used in the Treatment of COVID-19
Drug: Tetrandrine
Survival rate|body temperature
18 Years to 75 Years (Adult, Older Adult)
Phase 4
N=60
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 5, 2020-May 1, 2021
Tetrandrine Tablets, Jinhua, Zhejiang, China
https://ClinicalTrials.gov/show/NCT04308317
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine
Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs
Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events
6 Months to 80 Years (Child, Adult, Older Adult)
Phase 1|Phase 2
N=100
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 24, 2020-December 31, 2024
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
https://ClinicalTrials.gov/show/NCT04276896
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT
Drug: Bevacizumab
Proportion of patients whose oxygenation index increased by 100mmhg on the 7th day after admission
18 Years to 80 Years (Adult, Older Adult)
Not Applicable
N=118
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
March 12, 2020-May 31, 2020
Qilu Hospital of Shandong University, Jinan, Shandong, China
https://ClinicalTrials.gov/show/NCT04305106
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia
Drug: thalidomide|Drug: placebo
Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence
18 Years and older (Adult, Older Adult)
Phase 2
N=100
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
February 20, 2020-June 30, 2020
https://ClinicalTrials.gov/show/NCT04273529
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19
Drug: placebo|Drug: Thalidomide
Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment
18 Years and older (Adult, Older Adult)
Phase 2
N=40
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
February 18, 2020-May 30, 2020
https://ClinicalTrials.gov/show/NCT04273581
Fingolimod in COVID-19
Drug: Fingolimod 0.5 mg
The change of pneumonia severity on X-ray images
18 Years to 80 Years (Adult, Older Adult)
Phase 2
N=30
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 22, 2020-July 1, 2020
Wan-Jin Chen, Fuzhou, China
https://ClinicalTrials.gov/show/NCT04280588
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus
Biological: UC-MSCs|Other: Placebo
Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes
18 Years to 75 Years (Adult, Older Adult)
Not Applicable
N=48
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
February 24, 2020-February 1, 2021
Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04293692
Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)
Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）
Improvement time of clinical critical treatment index within 28 days|Side effects in the MSCs treatment group|Proportion of patients in each classification of clinical critical treatment index|All cause mortality on Day 28|Invasive mechanical ventilation rate|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Incidence of nosocomial infection|CD4+ T cell count by flow cytometry in two groups
18 Years to 70 Years (Adult, Older Adult)
Phase 1|Phase 2
N=60
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
March 5, 2020-December 31, 2021
Wuhan Huoshenshan Hospital, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04288102
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment
Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
18 Years to 75 Years (Adult, Older Adult)
Phase 4
N=520
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 23, 2020-February 28, 2021
Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf
https://ClinicalTrials.gov/show/NCT04286503
Efficacy and Safety of Corticosteroids in COVID-19
Drug: Methylprednisolone
the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days
18 Years and older (Adult, Older Adult)
Not Applicable
N=400
Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 14, 2020-May 30, 2020
Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China
https://ClinicalTrials.gov/show/NCT04273321
Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia
Other: severe covid-19 pneumonia with ET
Success rate of intubation|Infection rate of Anesthesiologist|Extubation time
18 Years to 90 Years (Adult, Older Adult)
N=120
Observational Model: Case-Only|Time Perspective: Prospective
March 7, 2020-July 30, 2020
https://ClinicalTrials.gov/show/NCT04298814
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment
Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events
18 Years and older (Adult, Older Adult)
Phase 2|Phase 3
N=300
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
February 27, 2020-January 2021
Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China
https://ClinicalTrials.gov/show/NCT04278963
Washed Microbiota Transplantation for Patients With 2019-nCoV Infection
Other: washed microbiota transplantation|Other: placebo
Number of participants with improvement from severe type to common type
14 Years to 70 Years (Child, Adult, Older Adult)
Not Applicable
N=0
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
February 5, 2020-April 30, 2020
Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
https://ClinicalTrials.gov/show/NCT04251767
Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : A Randomized Control Trial
Drug: Oral
SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment
16 Years to 100 Years (Child, Adult, Older Adult)
Phase 3
N=80
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 15, 2020-November 30, 2020
Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand
https://ClinicalTrials.gov/show/NCT04303299
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery
18 Years to 100 Years (Adult, Older Adult)
N=0
Observational Model: Cohort|Time Perspective: Retrospective
January 25, 2020-April 30, 2020
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
https://ClinicalTrials.gov/show/NCT04272710
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial
up to 18 Years (Child, Adult)
N=500
Observational Model: Cohort|Time Perspective: Prospective
February 15, 2020-December 31, 2020
Beijing Children's Hospital,, Beijing, China
https://ClinicalTrials.gov/show/NCT04270383
Prognostic Factors of Patients With COVID-19
all-cause mortality|Severe state
18 Years and older (Adult, Older Adult)
N=201
Observational Model: Cohort|Time Perspective: Retrospective
March 1, 2020-March 13, 2020
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
https://ClinicalTrials.gov/show/NCT04292964
Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment
changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events
18 Years and older (Adult, Older Adult)
Phase 2|Phase 3
N=116
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
March 20, 2020-June 30, 2021
Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04310865
Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
Drug: Chloroquine|Drug: Placebo
Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Duration of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Genetic loci and levels of biochemical components will be correlated with frequency of COVID-19, ARI and disease severity.
16 Years and older (Child, Adult, Older Adult)
Not Applicable
10000
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
May 2020
May 2022
https://ClinicalTrials.gov/show/NCT04303507
Immunoregulatory Therapy for 2019-nCoV
Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment
lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days
18 Years and older (Adult, Older Adult)
Phase 2
120
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
February 10, 2020
October 31, 2020
https://ClinicalTrials.gov/show/NCT04268537
Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic
Other: blood sample
To assess the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome "
Child, Adult, Older Adult
Not Applicable
1000
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
March 11, 2020
October 12, 2020
Hopital Pitié Salpetrière, Paris, France
https://ClinicalTrials.gov/show/NCT04304690
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray|Drug: Favipiravir Tablets
Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality
18 Years to 80 Years (Adult, Older Adult)
Not Applicable
60
Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 16, 2020
April 30, 2020
The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
https://ClinicalTrials.gov/show/NCT04273763
Mild/Moderate 2019-nCoV Remdesivir RCT
Drug: Remdesivir|Drug: Remdesivir placebo
Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events
18 Years and older (Adult, Older Adult)
Phase 3
308
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
February 12, 2020
April 27, 2020
Jin Yin-tan hospital, Wu Han, Hubei, China
https://ClinicalTrials.gov/show/NCT04252664
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus
Biological: MSCs
Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase
18 Years to 70 Years (Adult, Older Adult)
Phase 1
20
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
January 27, 2020
December 2021
Beijing 302 Military Hospital of China, Beijing, China
https://ClinicalTrials.gov/show/NCT04252118
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
Drug: Intravenous Immunoglobulin|Other: Standard care
Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events
18 Years and older (Adult, Older Adult)
Phase 2|Phase 3
80
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 10, 2020
June 30, 2020
https://ClinicalTrials.gov/show/NCT04261426
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir
Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA
18 Years and older (Adult, Older Adult)
Phase 4
400
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
February 1, 2020
July 1, 2020
Department and Institute of Infectious Disease, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04255017
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization
Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA
18 Years and older (Adult, Older Adult)
Phase 4
100
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
February 1, 2020
July 1, 2020
Department and Institute of Infectious Disease, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04254874
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir
Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery
18 Years to 55 Years (Adult)
Phase 3
60
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
February 1, 2020
July 1, 2020
Department and Institute of Infectious Disease, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04261270
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
Drug: Methylprednisolone
Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA
18 Years and older (Adult, Older Adult)
Phase 4
100
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
February 1, 2020
July 1, 2020
Department and Institute of Infectious Disease, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04263402
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo
High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index
18 Years to 65 Years (Adult, Older Adult)
Phase 2
136
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
February 15, 2020
December 2022
Shuguang Hospital, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04279197
CT Scores Predict Mortality in 2019-nCoV Pneumonia
Other: CT score
7-day mortality
Child, Adult, Older Adult
39
Observational Model: Cohort|Time Perspective: Retrospective
January 31, 2020
February 18, 2020
Wuhan third hospital, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04284046
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
Drug: Immunoglobulin of cured patients|Drug: γ-Globulin
Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality
18 Years and older (Adult, Older Adult)
Not Applicable
10
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 17, 2020
May 31, 2020
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04264858
Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System
Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform
Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform
16 Years to 100 Years (Child, Adult, Older Adult)
100
Observational Model: Cohort|Time Perspective: Retrospective
March 14, 2020
December 1, 2020
Huashan Hospital of Fudan University, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04311398
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019
Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab
Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time
18 Years to 65 Years (Adult, Older Adult)
Not Applicable
150
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 8, 2020
May 2020
Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China|Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04310228
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Biological: Dental pulp mesenchymal stem cells
Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen
18 Years to 75 Years (Adult, Older Adult)
Early Phase 1
24
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 5, 2020
July 30, 2021
https://ClinicalTrials.gov/show/NCT04302519
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment
Clinical recovery time
18 Years to 100 Years (Adult, Older Adult)
Not Applicable
80
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 14, 2020
April 14, 2021
https://ClinicalTrials.gov/show/NCT04295551
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy
Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells
18 Years to 80 Years (Adult, Older Adult)
120
Observational Model: Cohort|Time Perspective: Retrospective
February 20, 2020
June 20, 2020
Tongji Hospital, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04306705
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
Drug: T89
The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment
18 Years to 85 Years (Adult, Older Adult)
Not Applicable
120
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 26, 2020
September 15, 2020
https://ClinicalTrials.gov/show/NCT04285190
Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization
Drug: Losartan|Other: Placebo
Sequential Organ Failure Assessment (SOFA) Respiratory Score|28-Day Mortality|90-Day Mortality|Respiratory Failure Requiring Mechanical Ventilation|Number of 28-Day Ventilator-Free Days|Length of Hospital Stay|ICU Admission|ICU Length of Stay|Acute Kidney Injury|Hypotension Requiring Vasopressors|Sequential Organ Failure Assessment (SOFA) Total Score|Severity Assessment|Incidence of Respiratory Failure|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)
18 Years and older (Adult, Older Adult)
Phase 2
200
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
March 16, 2020
April 1, 2021
Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT04312009
Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
Drug: Losartan|Other: Placebo
Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Fever Incidence Day 3|Fever Incidence Day 5|Fever Incidence Day 7|Fever Incidence Day 10|Severity of Symptoms upon Hospital Admission
18 Years and older (Adult, Older Adult)
Phase 2
478
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
March 16, 2020
April 1, 2021
Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT04311177
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia
Biological: UC-MSCs|Drug: Placebo
Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio
18 Years to 65 Years (Adult, Older Adult)
Not Applicable
48
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 16, 2020
February 15, 2022
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04273646
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
Drug: Arbidol|Other: basic treatment
Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count
18 Years to 75 Years (Adult, Older Adult)
Phase 4
380
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 7, 2020
December 30, 2020
https://ClinicalTrials.gov/show/NCT04260594
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
Drug: Bevacizumab Injection
Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality
18 Years to 80 Years (Adult, Older Adult)
Phase 2|Phase 3
20
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 2020
May 2020
Qilu Hospital of Shandong University, Jinan, Shandong, China
https://ClinicalTrials.gov/show/NCT04275414
Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress
Drug: Aviptadil by intravenous infusion|Drug: Aviptadil by endotracheal nebulization
Mortality|PO2
18 Years to 100 Years (Adult, Older Adult)
Phase 2
20
Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
April 2020
September 2020
Research Facility, New York, New York, United States|Rambam Health Care Campus, Haifa, Israel
https://ClinicalTrials.gov/show/NCT04311697
Evaluation of Ganovo （Danoprevir ）Combined With Ritonavir in the Treatment of Novel Coronavirus Infection
Drug: Ganovo+ritonavir+/-Interferon atomization|Drug: Long acting interferon|Drug: Recombinant cytokine gene-derived protein|Drug: Lopinavir+ritonavir|Drug: Chinese medicines +interferon atomization
Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event
18 Years to 75 Years (Adult, Older Adult)
Phase 4
50
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 17, 2020
April 30, 2020
The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China
https://ClinicalTrials.gov/show/NCT04291729
Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19
Other: mobile internet survey on self-test
positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient
Child, Adult, Older Adult
300000
Observational Model: Other|Time Perspective: Prospective
February 1, 2020
July 31, 2020
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04256395
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 Infection
Drug: Nitric Oxide
Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery
18 Years and older (Adult, Older Adult)
Phase 2
240
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 13, 2020
April 1, 2022
https://ClinicalTrials.gov/show/NCT04305457
Adaptive COVID-19 Treatment Trial
Other: Placebo|Drug: Remdesivir
Percentage of subjects reporting each severity rating on the 7-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of severe adverse events (AEs)|Discontinuation temporary suspension of infusions|Duration of hospitalization|Duration of new mechanical ventilation|Duration of new oxygen use|Incidence of new mechanical ventilation|Incidence of new oxygen use|Mean change in the ordinal scale from baseline|Number of oxygenation free days|Number of ventilator free days|Subject clinical status using ordinal scale|Subject mortality|Time to an improvement of one category from admission using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first
18 Years to 99 Years (Adult, Older Adult)
Phase 2
394
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
February 21, 2020
April 1, 2023
University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Emory Clinic - Investigational Drug Service, Atlanta, Georgia, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|National Centre for Infectious Diseases (NCID), Singapore, Singapore
https://ClinicalTrials.gov/show/NCT04280705
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
Drug: Nitric Oxide
Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery
18 Years and older (Adult, Older Adult)
Phase 2
240
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 1, 2020
February 1, 2022
https://ClinicalTrials.gov/show/NCT04290858
Eculizumab (Soliris) in Covid-19 Infected Patients
Drug: Eculizumab
18 Years and older (Adult, Older Adult)
https://ClinicalTrials.gov/show/NCT04288713
Severe 2019-nCoV Remdesivir RCT
Drug: Remdesivir|Drug: Remdesivir placebo
Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events
18 Years and older (Adult, Older Adult)
Phase 3
453
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
February 6, 2020
May 1, 2020
Bin Cao, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04257656
Influence of the COvid-19 Epidemic on STRESS
Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits
Child, Adult, Older Adult
50000
Observational Model: Cohort|Time Perspective: Cross-Sectional
March 11, 2020
March 2022
University Hospital, Clermont-Ferrand, Clermont-Ferrand, France
https://ClinicalTrials.gov/show/NCT04308187
Blood Donor Recruitment During Epidemic of COVID-19
Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information
Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks
18 Years to 60 Years (Adult)
Not Applicable
1500
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research
March 12, 2020
April 9, 2020
https://ClinicalTrials.gov/show/NCT04306055
Medical Masks vs N95 Respirators for COVID-19
Device: Medical Mask|Device: N95 respirator
RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death
18 Years and older (Adult, Older Adult)
Not Applicable
576
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
April 1, 2020
January 1, 2021
https://ClinicalTrials.gov/show/NCT04296643
Accurate Classification System for Patients With COVID-19 Pneumonitis
survival status
Child, Adult, Older Adult
669
Observational Model: Other|Time Perspective: Retrospective
December 10, 2019
March 4, 2020
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04302688
The Investigation of the Neonates With or With Risk of COVID-19
The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19
up to 28 Days (Child)
100
Observational Model: Case-Only|Time Perspective: Prospective
February 1, 2020
December 31, 2020
Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04279899
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
Drug: Nitric Oxide Gas
SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air
18 Years and older (Adult, Older Adult)
Phase 2
104
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
March 1, 2020
March 1, 2022
https://ClinicalTrials.gov/show/NCT04290871
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Child, Adult, Older Adult
15
Observational Model: Case-Only|Time Perspective: Prospective
February 1, 2020
December 31, 2020
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04292340
Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool
Other: Nutrition support
28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation
18 Years and older (Adult, Older Adult)
100
Observational Model: Cohort|Time Perspective: Prospective
February 2020
July 2020
https://ClinicalTrials.gov/show/NCT04274322
Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients
Drug: Recombinant human interferon α1β
The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.
18 Years and older (Adult, Older Adult)
Early Phase 1
328
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
March 1, 2020
June 30, 2020
https://ClinicalTrials.gov/show/NCT04293887
Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations
Positive rate of 2019 Novel Coronavirus RNA|Survival rate
Child, Adult, Older Adult
20
Observational Model: Cohort|Time Perspective: Prospective
January 20, 2020
February 28, 2021
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
https://ClinicalTrials.gov/show/NCT04279795
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection
Other: Comprehensive treatment
Survival rate|Chest computed tomography|Recovery Time|Depression evaluation
Child, Adult, Older Adult
100
Observational Model: Cohort|Time Perspective: Prospective
January 20, 2020
February 28, 2021
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
https://ClinicalTrials.gov/show/NCT04279782
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
Mortality|The time interval of Nucleic acid detection become negative
18 Years to 75 Years (Adult, Older Adult)
400
Observational Model: Other|Time Perspective: Retrospective
January 1, 2020
July 31, 2020
Fujian Provincial Hospital, Fuzhou, Fujian, China
https://ClinicalTrials.gov/show/NCT04292327
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia
Biological: UC-MSCs
Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)
18 Years to 75 Years (Adult, Older Adult)
Phase 2
10
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
February 6, 2020
September 30, 2020
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04269525
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group
The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal
18 Years to 75 Years (Adult, Older Adult)
Not Applicable
160
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 7, 2020
June 30, 2020
https://ClinicalTrials.gov/show/NCT04261907
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
Drug: VC|Drug: Sterile Water for Injection
Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores
18 Years and older (Adult, Older Adult)
Phase 2
140
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
February 14, 2020
September 30, 2020
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04264533
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization
Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia
18 Years to 70 Years (Adult, Older Adult)
Not Applicable
348
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 14, 2020
December 14, 2021
https://ClinicalTrials.gov/show/NCT04275388
Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV
Diagnostic Test: Recombinase aided amplification (RAA) assay
Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%
1 Year to 90 Years (Child, Adult, Older Adult)
50
Observational Model: Cohort|Time Perspective: Prospective
January 1, 2020
December 31, 2020
Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04245631
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection
Biological: mRNA-1273
Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted
18 Years to 55 Years (Adult)
Phase 1
45
Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
March 3, 2020
June 1, 2021
Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States
https://ClinicalTrials.gov/show/NCT04283461
2019-nCoV Outbreak and Cardiovascular Diseases
Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety
Child, Adult, Older Adult
N=12000
Observational Model: Case-Only|Time Perspective: Prospective
January 20, 2020
April 30, 2020
Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China
https://ClinicalTrials.gov/show/NCT04255940
Social Media Use During COVID-19
Behavioral: Use of social media during COVID-19
Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic
21 Years and older (Adult, Older Adult)
5000
Observational Model: Cohort|Time Perspective: Cross-Sectional
March 8, 2020
May 31, 2020
Yale-NUS College, Singapore, Singapore
https://ClinicalTrials.gov/show/NCT04305574
Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus
Other: nosocomial infection/hospital acquired infection
nosocomial infection
Child, Adult, Older Adult
300
Observational Model: Cohort|Time Perspective: Prospective
March 9, 2020
October 30, 2020
Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France
https://ClinicalTrials.gov/show/NCT04290780
Nitric Oxide Gas Inhalation for SARS-CoV-2
Drug: Nitric Oxide Gas
Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment
18 Years to 99 Years (Adult, Older Adult)
Phase 2
200
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
March 10, 2020
March 10, 2022
https://ClinicalTrials.gov/show/NCT04306393
A New Screening Strategy for 2019 Novel Coronavirus Infection
Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy
Screening accuracy|Cost-effectiveness analysis
Child, Adult, Older Adult
Not Applicable
230
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening
February 2020
March 2020
the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04281693
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection
Biological: 2019-nCoV PCR
Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact
Child, Adult, Older Adult
300
Observational Model: Cohort|Time Perspective: Prospective
February 4, 2020
February 4, 2021
CIC 1425, Paris, France
https://ClinicalTrials.gov/show/NCT04259892
Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV
Drug: Darunavir and Cobicistat
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2
Child, Adult, Older Adult
Phase 3
30
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
January 30, 2020
December 31, 2020
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04252274
Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )
Drug: Hydroxychloroquine
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2
18 Years and older (Adult, Older Adult)
Phase 3
30
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 6, 2020
December 31, 2020
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
https://ClinicalTrials.gov/show/NCT04261517
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection
Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment
14 Years to 80 Years (Child, Adult, Older Adult)
Not Applicable
150
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
January 22, 2020
January 22, 2021
The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04251871
A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia
GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)
Child, Adult, Older Adult
N=30000
Observational Model: Case-Only|Time Perspective: Prospective
February 3, 2020
April 20, 2020
Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
https://ClinicalTrials.gov/show/NCT04260308
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
Drug: Meplazumab for Injection
2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status
18 Years to 75 Years (Adult, Older Adult)
Phase 1|Phase 2
20
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 3, 2020
December 31, 2020
Tangdu Hospital, Xi'an, Shaanxi, China
https://ClinicalTrials.gov/show/NCT04275245
Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life
Other: standard operating procedures
Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management
18 Years and older (Adult, Older Adult)
50
Observational Model: Cohort|Time Perspective: Prospective
March 19, 2020
December 31, 2020
Luigi Sacco University Hospital, Milan, Lombardia, Italy
https://ClinicalTrials.gov/show/NCT04307459
Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis
Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR
18 Years to 60 Years (Adult)
Phase 2
20
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment
April 10, 2020
November 10, 2020
https://ClinicalTrials.gov/show/NCT04299152
Expanded Access Remdesivir (RDV; GS-5734™)
Drug: Remdesivir
Child, Adult, Older Adult
https://ClinicalTrials.gov/show/NCT04302766
Sero-epidemiological Survey of England in 2019/2020
Procedure: venepuncture
Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment
up to 24 Years (Child, Adult)
2300
Observational Model: Other|Time Perspective: Prospective
October 15, 2019
November 30, 2020
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom
https://ClinicalTrials.gov/show/NCT04061382
Clinical Outcomes of Patients With COVID19
Other: retrospective analysis
Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation
Child, Adult, Older Adult
50
Observational Model: Cohort|Time Perspective: Retrospective
February 22, 2020
March 31, 2020
HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China
https://ClinicalTrials.gov/show/NCT04280913
NK Cells Treatment for Novel Coronavirus Pneumonia
Biological: NK Cells
Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging
18 Years to 65 Years (Adult, Older Adult)
Phase 1
30
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 20, 2020
December 30, 2020
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
https://ClinicalTrials.gov/show/NCT04280224
Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure
Drug: methylprednisolone therapy|Other: Standard care
Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality
18 Years and older (Adult, Older Adult)
Phase 2|Phase 3
80
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
January 26, 2020
December 25, 2020
Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China
https://ClinicalTrials.gov/show/NCT04244591
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B
Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens
18 Years and older (Adult, Older Adult)
Phase 2
70
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 10, 2020
July 31, 2022
University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
https://ClinicalTrials.gov/show/NCT04276688
Post-exposure Prophylaxis for SARS-Coronavirus-2
Drug: Hydroxychloroquine|Other: Placebo
Incidence of COVID19 Disease|Ordinal Scale of COVID19 Disease Severity|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal
18 Years and older (Adult, Older Adult)
Phase 2|Phase 3
1500
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
April 2020
May 2021
University of Minnesota, Minneapolis, Minnesota, United States
https://ClinicalTrials.gov/show/NCT04308668
Clinical Characterisation Protocol for Severe Emerging Infections
Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants
Child, Adult, Older Adult
500
Observational Model: Other|Time Perspective: Prospective
February 7, 2020
August 7, 2023
CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de réanimation médicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France
https://ClinicalTrials.gov/show/NCT04262921
A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia
Biological: MSCs-derived exosomes
Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality
18 Years to 75 Years (Adult, Older Adult)
Phase 1
30
Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
February 15, 2020
July 31, 2020